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Abstract
Background: It remains challenging to characterize the functional attributes of chimeric antigen receptor
(CAR)-engineered T cell product targeting CD19 related to potency and immunotoxicity ex vivo, despite
promising in vivo efficacy in patients with B cell malignancies.
Methods: We employed a single-cell, 16-plex cytokine microfluidics device and new analysis techniques to evaluate
the functional profile of CD19 CAR-T cells upon antigen-specific stimulation. CAR-T cells were manufactured from
human PBMCs transfected with the lentivirus encoding the CD19-BB-z transgene and expanded with anti-CD3/anti-
CD28 coated beads. The enriched CAR-T cells were stimulated with anti-CAR or control IgG beads, stained with anti-
CD4 RPE and anti-CD8 Alexa Fluor 647 antibodies, and incubated for 16 h in a single-cell barcode chip (SCBC). Each
SCBC contains ~12,000 microchambers, covered with a glass slide that was pre-patterned with a complete copy of a
16-plex antibody array. Protein secretions from single CAR-T cells were captured and subsequently analyzed using
proprietary software and new visualization methods.
Results: We demonstrate a new method for single-cell profiling of CD19 CAR-T pre-infusion products prepared from 4
healthy donors. CAR-T single cells exhibited a marked heterogeneity of cytokine secretions and polyfunctional
(2+ cytokine) subsets specific to anti-CAR bead stimulation. The breadth of responses includes anti-tumor
effector (Granzyme B, IFN-γ, MIP-1α, TNF-α), stimulatory (GM-CSF, IL-2, IL-8), regulatory (IL-4, IL-13, IL-22), and
inflammatory (IL-6, IL-17A) functions. Furthermore, we developed two new bioinformatics tools for more effective
polyfunctional subset visualization and comparison between donors.
Conclusions: Single-cell, multiplexed, proteomic profiling of CD19 CAR-T product reveals a diverse landscape
of immune effector response of CD19 CAR-T cells to antigen-specific challenge, providing a new platform for
capturing CAR-T product data for correlative analysis. Additionally, such high dimensional data requires new
visualization methods to further define precise polyfunctional response differences in these products. The presented
biomarker capture and analysis system provides a more sensitive and comprehensive functional assessment of CAR-T
pre-infusion products and may provide insights into the safety and efficacy of CAR-T cell therapy.
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Background
Adoptive immunotherapy is a novel treatment modality for
human cancers [1, 2]. One such approach, CAR-T cell
therapy, involves the use of viral vectors to genetically
modify autologous T cells to express a chimeric antigen
receptor (CAR) directed against a tumor antigen [2]. CD19
CAR-T, arguably the most successful CAR-T cell therapy to
date in the clinic, involves genetically engineering autolo-
gous T cells ex vivo to express CARs against a B-lineage
antigen CD19, which is expressed on tumor cells such as
diffuse large B-cell lymphoma (DLBCL) and B-cell precur-
sor acute lymphocytic leukemia (B-ALL) [3–5]. While
striking results with a high rate of complete remission
(67%–90%) have been observed in clinical trials in adults
and children with relapsed/refractory B-ALL [3, 5–8],
encouraging, yet variable, results have been reported with
other B-cell malignancies treated by CD19 CAR-T therapy.
An overall response rate of 57% (4 complete responders
and 4 partial responders out of 14 patients) was reported in
a small trial on relapsed/refractory chronic lymphocytic
leukemia (CLL) and a complete response rate of 57% (4 out
of 7 patients) was reported in a phase I study with
chemotherapy-refractory DLBCL [9]. These variable clinical
responses across patients may result from many factors
such as pre-conditioning regimen of patients, CAR-T cell
administration procedure as well as T cell sources and
manufacturing process. However, the key contributors to
the variations are not fully identified [10, 11]. High-
resolution single-cell analysis of functional attributes of
CAR-T pre-infusion products may provide new insights
into the variability of clinical responses and open up new
avenues for the development of more efficacious yet safe
CAR-T cell therapy.
In an in vitro system, the reorganization of tumor anti-
gen by CAR, are followed by a wave of signals that
comprise the secretion of cytolytic enzymes, stimulatory
cytokines, and chemoattractive proteins. How these
signals reflect CAR-T function in patient is minimally
characterized and poorly understood. This is further
compounded by the secretion of immunosuppressive
cytokines that reduce the efficacy of treatment or pro-in-
flammatory cytokines involved in immunotoxic side ef-
fects such as cytokine release syndrome (CRS) [12].
Moreover, this signal, which varies between patients and
differs in individual CAR-T cells, is difficult to control or
standardize, highlighting a pressing need to systematical
evaluate the ability of engineered CAR-T cell product to
release these signals following an antigen-specific chal-
lenge and to link this capability to clinical outcomes.
It is well accepted that T cells capable of co-producing
multiple cytokines/chemokines at the single cell level,
termed “polyfunctional” T cells, are the key effector cells
contributing to the development of potent and durable cel-
lular immunity against viral infection or cancer [13–16].
The same principle is expected to apply to engineered
CAR-T cells in autologous cellular immunotherapy. Porter
et al. showed that CD19 CAR-T-cells collected from CLL
patients following treatment are indeed polyfunctional
measured by 6-color ICS-FC [9]. Four patients exhibited
complete remissions, and, for those patients, their CAR-T
cells persist and retain polyfunctionality for up to 4 years
post infusion [9]. This study highlighted the importance of
polyfunctionality, for therapeutic efficacy of anti-tumor
CAR-T cells. While most studies characterized single-cell
cytokine production in CD19 CAR-T cells using intracellu-
lar staining flow cytometry (ICS-FC) [17], the limited
number of cytokine/chemokines measured per single cell
undermines the capability to comprehensively assess CAR-
T polyfunctionality.
A comprehensive assessment of CAR-T polyfunctionality
has become possible with the development of a single-cell
barcode chip (SCBC) microdevice that demonstrated
simultaneous measurement of up to 42 cytokines secreted
from single cells and thousands of single cells analyzed in
parallel per device [18]. In the current study, we apply this
microdevice technology to CD19 CAR-T cells to delineate
the landscape of effector function capability in response to
antigen-specific stimulation. We were able to load small
quantities of CAR+ T cells onto the device and distinguish
CD4 and CD8 cells using high content imaging cytometry.
We then simultaneously measured 16 cytokines/chemo-
kines from thousands of single CAR-T cells. Elevated
cytokine/chemokine levels in response to antigen specific
stimulation at the single-cell level were observed for cells
generated from all 4 donors, albeit with significant donor-
to-donor variation. Significant subsets of stimulated CAR-T
cells exhibit high polyfunctionality with a dominant anti-
tumor effector cytokine profile. New bioinformatics tools
were developed to visualize polyfunctional T cell subsets
and compare across donors. The analysis revealed distinct
functional clusters from each donor and provided a land-
scape of CD19 CAR-T cell effector functions upon antigen
stimulation. The comprehensive single CAR-T cell analysis
paves the way to understand the relationship between in
vitro function profiles and therapeutic outcomes.
Methods
Fabrication of antibody barcode slides
The silicon master for antibody barcode manufacturing,
polydimethyl siloxane (PDMS) was etched with the
deep-reactive-ion etching (DRIE) method. It was pre-
treated with trimethylchlorosilane (Sigma-Aldrich) vapor
in a vacuum desiccator for 30 min. The master was then
compressed into an acrylic base, to form the mold for
PDMS chips. The PDMS pre-polymer elastomer base
and curing agent, Sylgard 184 (Dow Corning) was mixed
completely (parts A and B in a 10:1 ratio) and placed in
a vacuum desiccator for 30 min to remove air bubbles.
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The mixture was then injected into the mold using a
syringe and the mold was cured in the oven at 80 °C for
1.5 h. After curing, the PDMS layer was removed from
the mold and holes for the inlet and outlet ports were
punched. Each flow-patterning PDMS chip measured
75 mm (length) × 25 mm (width) × 6 mm (height). The
PDMS microchip contained 20 separate microchannels
(20 μM width × 20 μM depth) arranged in a serpentine
pattern across the chip that can pattern up to 20 differ-
ent solutions respectively. The PDMS microchip was
then bound to a poly-L-lysine glass slide to form an anti-
body flow pattern device. 2 μL of different capture
antibodies (Additional file 1) were flowed into each
microchannel through the PDMS chip for 3 h. The anti-
bodies were immobilized on the glass slide by binding to
the poly-L-lysine. After flow patterning, the PDMS was
removed from the slide and the antibody barcode slide
was blocked for 30 min in 3% BSA/PBS. The slide was
then washed sequentially in PBS (Lonza), 50% PBS/DI
water, DI water, DI water and dried for 30 s in a Labnet
slide spinner (C1303-T). The slide was vacuum sealed
and stored indefinitely at −20 °C prior to use.
Fabrication of microchamber array chips
The PDMS microchamber array chip was prepared using
the microchamber array silicon master following the
same steps as described above. The PDMS microcham-
ber array chips were 25 mm (width) × 55 mm (length) ×
4.75 mm (height). Each array contained 24 columns of
530 microchambers per column (totaling 12,720 micro-
chambers per chip). Each microchamber measured
20 μM (width) × 2060 μM (length) × 20 μM (depth) for
a total volume of ~1.2 nL per chamber.
Generation of healthy CD8 T cells
Healthy PBMCs were isolated from whole blood (StemCell)
using Ficoll-Paque Plus (GE Healthcare) density gradient
centrifugation at 300 g for 20 min. The interphase containing
PBMC was harvested and stimulated in complete X-VIVO
15 media (Lonza) at a cell density of 1 × 107/mL with immo-
bilized anti-CD3 antibody (10 μg/mL, eBioscience) and
soluble anti CD28 antibody (4 μg/mL, eBioscience) at 37 °C,
5% CO2 for 48 h. The CD8 T cells then were enriched by
magnetic bead-conjugated anti-CD8 antibody (Miltenyi-
Biotec) prior to SCBC assay and ICS assay.
ICS assay of healthy CD8 T cells
The enriched CD8 T cells were stimulated with PMA
(50 ng/mL, Sigma-Aldrich) and Ionomycin (1 μg/mL,
Sigma-Aldrich) at a density of 1 × 106/mL in fresh
complete X-VIVO 15 media at 37 °C, 5% CO2 for 6 h with
brefeldin A (1 μg/mL, eBioscience) the last 3 h. Cells were
then fixed with 4% paraformaldehyde (Sigma-Aldrich),
permeabilized with 0.5% saponin (Sigma-Aldrich), and
stained with PE-conjugated anti-IFN-γ /PE-CY7-conju-
gated anti-TNF-α. The cells were acquired by S3e cell
sorter (BioRad) and analyzed by Flowjo software v10
(TreeStar Inc.).
Generation of CD19 CAR-T cells
The CD19-BB-z transgene lentiviral vector was designed
and produced as described before [3, 19, 20]. Apheresis of
healthy donors (2 females and 2 males with age range 26–
51) was obtained from HemaCare. Methods of CAR-T cell
preparation have been previously described [20–23].
Briefly, peripheral blood mononuclear cells (PBMCs) were
isolated from the apheresis and activated with anti-CD3/
anti-CD28 monoclonal antibody-coated magnetic beads
(Thermo Fisher) in a modified X-VIVO 15 media. Cells
were transduced with a lentiviral vector encoding the
CD19-BB-z transgene and ex vivo expanded in a closed
system for 10 days. Cell concentration was monitored dur-
ing the expansion process and fresh medium was added
every 2–3 days. On the day of harvest, transduced CAR-T
cells were isolated from the population using anti-PE
microbeads (Miltenyi) following the manufactures’ in-
struction. Briefly, cells were incubated with a PE conju-
gated antibody specific for CARs on cell surface, followed
by a second incubation with anti-PE microbeads. After
wash, the cell-beads mixture was passed through a LS
(Miltenyi) column in a MACS separator. Following an-
other wash step, the CAR positive fraction was collected
by plunging out the column-retaining cells and cryopre-
served. The collected cells were analyzed using flow
cytometry to confirm that >90% of the cells were CAR+.
Before any assay, cryopreserved CAR-T cells were thawed
and cultured overnight at a concentration of 1 × 106 cells/
mL in X-VIVO 15 media. Immediately prior to use, dead
cells were removed from culture using a Dead Cell Re-
moval Kit (Miltenyi) and LS Magnetic Column (Miltenyi).
Conjugation of Dynabeads for stimulation
The tosylactivated M-450 Dynabeads (Invitrogen) were
conjugated with a CAR specific antibody following the
manufacturers’ instructions. In short, 4E8 beads were
incubated with 200 μg antibodies for 24 h. After exten-
sive wash, the beads were aliquoted and stored at 4 °C
until use. Beads conjugated with non-specific IgG were
generated as the same time and used as negative control.
CAR-T cell population assays
CD19 CAR-T cells (1 × 106 cells/mL) were mixed at a
1:4 ratio with beads and cultured in wells of a 96 well
tissue culture plate for 24 h. The supernatant was
harvested and analyzed using a human IFN-γ quantikine
ELISA kit (R&D) or a multiplexing population assay
developed in house. The ELISA assay was performed
following manufacturer’s instructions. Briefly, the assay
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plate was incubated with samples, antibody conjugate,
substrate solution and stop solutions in sequential order.
The plate was read using a SpectraMax M5 plate reader
(Molecular Device). The multiplexing population assay
was performed using a custom PDMS device. A custom
12-hole PDMS microwell slab (each hole at D = 1 cm)
was placed on top of a 16-plex antibody barcode slide to
form a multiplexing 12-well assay device. The two
components were tightly clamped with screws using a
custom polycarbonate plate clamping system. 50 μL of
cell culture supernatant was added to each well and
incubated for 1 h. Following incubation, the wells were
washed 3 times with 1% BSA/PBS and then incubated
with 50 μL of detection antibody cocktail (1:200 dilution
in 1% BSA/PBS, Additional file 1) for 1 h. The wells
were then washed again 3 times with 1% BSA/PBS and
incubated with 50 μL of APC streptavidin (1:100 dilution
in 1% BSA/PBS, BioLegend) solution for 30 min. After
washing 5 times with 1% BSA/PBS, the slide was
removed from the clamp. The slide was washed in a
Coplin jar for 3 min at 125 rpm sequentially using PBS,
50% PBS/DI water, DI water, DI water sequentially. The
slide was then dried for 30 s in a Labnet slide spinner
(C1303-T), scanned with a GenePix 4400A micro-
array scanner and analyzed using IsoPlexis’ propri-
etary IsoSpeak software.
Preparation of cell suspension for SCBC assay
The healthy CD8 T cells from healthy PBMCs were sus-
pended at a density of 1.25 × 106/mL in fresh complete
X-VIVO 15 media with the addition of PMA (50 ng/mL)
and Ionomycin (1 μg/mL). CD19 CAR-T cells (1 × 106
cells/mL) were mixed with beads at a 1:4 ratio. The mix-
ture was plated into a single well of a 96-well plate and
incubated at 37 °C for 6 h. Stimulated cells were then
collected and incubated with anti-human CD4 RPE
antibody (1:100 dilution, Thermo Fisher) and anti-
human CD8a Alexa Fluor 647 antibody (1:100 dilution,
BioLegend) at room temperature for 10 min. The cells
were then spun at 300 g for 10 min and re-suspended in
fresh media at a density of 1.25 × 106 cells/mL.
SCBC assay
The PDMS microchamber array was plasma treated for
2.5 min with a Plasma Etch PE-25 plasma cleaner and
blocked in 3% BSA/PBS for 30 min. Immediately before
the assay, the PDMS chamber was rinsed with media
and blown dry using compressed air. It was then placed
on a glass slide and secured into a custom clamping
system. 30 μL of cell suspension was pipetted onto the
microchamber array chip. The antibody barcode slide
was put on top of the microchamber PDMS with the
antibody side facing down. The whole system was
clamped tightly in a custom clamping system. The system
was imaged immediately as described in Microchamber
array imaging. Post imaging, the microchamber assembly
was placed in a standard 5% CO2, incubator at 37 °C for
16 h. Following incubation, the microchamber system was
dissembled in a 1% BSA/PBS bath and the antibody slide
was removed and rinsed with 1% BSA/PBS. The slide was
then incubated with 300 μL detection antibody cocktail
(Additional file 1) for 45 min. Each detection antibody is
at a concentration of 0.25 μg/mL in 1% BSA/PBS solution.
Following this step, the barcode slide was rinsed with 1%
BSA/PBS and incubated with 300 μL APC streptavidin
solution (1:100 dilution in 1% BSA/PBS, BioLegend) for
30 min. The slide was rinsed with 1% BSA/PBS again and
then washed in Coplin jars sequentially using PBS, 50%
PBS/DI water, DI water, DI water for 3 min at 125 rpm.
The slides were dried for 30 s in a Labnet slide spinner
(C1303-T) and scanned using a GenePix microarray scan-
ner as described in Antibody barcode slide imaging.
Microchamber array imaging
The assembled microchamber system was imaged using a
Zeiss Axio Observer.Z1 fluorescent microscope with a
Hamamatsu Orca-Flash4.0 LT Digital CMOS camera
(C11440-42 U) and an automatic stage. For each micro-
chamber array, bright field images were taken to visualize
the microchambers and fluorescent images were taken to
visualize cells labeled with CD4 or CD8 antibodies. A set
of 253 tiles (5X image) or 494 tiles (10X image) was taken
for the entire array (54183uM x 24866uM). Using Zen2
Pro software, the tiles were exported as TIFF image files
for analysis.
Antibody barcode slide imaging
A GenePix 4400A scanner (Molecular Devices) was used
to scan the antibody barcode slides. Each slide was
scanned using a GenePix Pro software (Molecular
Devices) at two color channels, 488 (blue, PMT 350,
Power 90) and 635 (red, PMT 600, Power 90). The image
was then exported as a TIFF file for analysis.
Image processing and data analysis
All data extraction and visualizations were performed
using IsoPlexis’ IsoSpeak software package. The applica-
tion was developed using C++ and the QT application
framework, and used the open source OpenCV library
for image processing. The microchamber array images
and antibody barcode images were overlaid based on
visual alignment markers embedded in the SCBC. Cell
counts and phenotypes in each microchamber could
therefore be mapped to the corresponding cytokine/che-
mokine levels. The software automatically located cell
chambers using edge and contour detection. The soft-
ware identified and counted cells in each microchamber
based on fluorescence intensities in the fluorescence
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images and feature detection in the brightfield image.
Cell subsets (CD4/CD8) were further determined based
on immunofluorescence. User verification was per-
formed on a small subset (normally around 2–3% of the
whole array) to validate the automatic results. The soft-
ware analyzed the antibody barcode image to determine
the location of each antibody lane, using Hough trans-
forms and subsequent interpolation. The raw intensity
value of each cytokine readout from each single-cell was
extracted from the image region where the single cell
microchamber overlaps the cytokine’s corresponding
antibody lane. Zero-cell microchambers and their associ-
ated protein signals were used to assess cytokine-specific
background. A background threshold was computed per
cytokine, defined as three standard deviations above the
average zero-cell signal intensity. Signals with a signal-
to-noise ratio (SNR) of at least 2 (relative to the back-
ground threshold) were considered as true protein
signals. If at least 20 single cells or 2% of all single cells
(whichever quantity was larger) showed true protein
signal for one specific cytokine, this cytokine was labeled
as significantly secreted by the sample. Knowing the
secretion profile of each single-cell, the frequency of all
polyfunctional groups present in the sample were identi-
fied. From these frequencies and the background-
subtracted signal intensities, the polyfunctional strength
of the sample, and the percent contribution from each
cytokine group was found. PAT PCA transformations
were performed as outlined in Additional file 2: Figure S3.
All visualizations were automatically generated in Iso-
Speak from the above data.
Results
Study design - highly multiplexed measurement of
cytokine secretions from single CD19 CAR-T cells upon
antigen-specific stimulation
To capture the full spectrum of complex T cell functions
within the heterogeneous CAR-T population, we ana-
lyzed CAR-T cytokine production at the single cell level
using a 16-plex panel. The 16-plex cytokine assay panel
includes the key immune functions of T cells (e.g. ef-
fector, stimulatory, regulatory and inflammatory) (Fig. 1b
& Additional file 3) and has been validated at both a
population level and a single-cell level (Additional files 4
and 5). CAR-T cells generated from 4 different healthy
donors were analyzed for cytokine secretion at the single
cell level. The enriched CAR+ T cells were stimulated
with anti-CAR beads or control IgG beads, stained with
anti-CD4-PE and anti-CD8-AF647 and loaded into SCBC
microchips for single cell cytokine analysis (Fig. 1a). Each
of SCBC microchip device is comprised of a polydimethyl
siloxane (PDMS) microchamber layer and a glass slide
(see schematic in Fig. 1c(i)). The supporting glass slide is
surface patterned with a miniaturized 16-element
antibody microarray (Fig. 1c). The design of the SCBC
permits optical microscopy inspection of the individual
microchambers (Fig. 1c(ii)), including number of cells in
each well and the cellular phenotypes (e.g., CD4+, CD8+,
etc.) based on surface marker staining. The fluorescence
based cytokine data is merged with the microscopy im-
aging data to generate the final data set. The number of
cells, the cell phenotype and the cytokine production are
therefore specified for each microchamber. We further
adopted and/or developed advanced informatics tools (in
IsoPlexis’ IsoSpeak software package) for not only statis-
tical analysis of SCBC data sets but also the dissection of
functional subsets (Fig. 1c (iii)). To evaluate the specificity
of anti-CAR bead stimulation, CAR-T cells were stimu-
lated with anti-CAR or IgG control beads in wells of 96-
well plate for 24 h and the supernatant was analyzed by
ELISA. Anti-CAR stimulation showed approximately
1000-fold increase of IFN-γ compared to control IgG
beads stimulation (Fig. 1d), indicating the good specificity
of in vitro anti-CAR bead stimulation. In addition, the
increased cytokine secretion levels in CD19 CAR-T cells
upon anti-CAR bead stimulation were observed across 4
donors compared to IgG control bead stimulation at a
single-cell level, further demonstrating the stimulation
specificity (Additional files 3 & 6).
Increased polyfunctional heterogeneity of activated CD19
CAR-T cells dominated by an effector cytokine profile
upon anti-CAR bead stimulation
Given that the frequency of polyfunctional effector T
cells correlates with potency of anti-tumor or anti-
virus T cell immunity [24–26], we assessed the poly-
functionality of our CAR-T cell products. First, we
computed the percentage of polyfunctional cells re-
gardless of the combination of cytokines co-produced.
As shown in Fig. 2a, under 5% of cells with IgG bead
stimulation exhibited polyfunctionality. By contrast,
the anti-CAR bead-stimulated CAR-T cells of donors
1–4 respectively showed a 6-, 2-, 47-, and 11-fold in-
crease in polyfunctional cell counts for 4 donors,
highlighting both the polyfunctionality and variability
of CAR-T products across donors. In all 4 donors, we
also noted that anti-CAR bead-stimulated CD8+ T
cells were more polyfunctional than CD4+ T cells.
Moreover, we used the polyfunctional strength index
(PSI) described previously to quantify the collective
impact of polyfunctional T cells [27]. The PSI of a
sample is defined as the percentage of polyfunctional
cells multiplied by the average signal intensity of the
cytokines secreted by these cells. We further broke
down PSI by cytokine function (Fig. 2b) – effector,
stimulatory, regulatory, and inflammatory – to high-
light the contribution of each group to the overall
polyfunctionality of the sample. The PSI breakdown
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in Fig. 2b further revealed inter-donor heterogeneity
of polyfunctional CAR-T cells. While effector and
stimulatory cytokines contribute the most to poly-
functionality across all 4 donors, a small portion of
regulatory and inflammatory cytokines were observed
in donor 1 and donor 4. Furthermore, the observed
regulatory and inflammatory response was mainly
from the CD4+ T cells, consistent with the notion
that both regulatory and helper T cells are subsets of
CD4+ T cells, further proving the specificity of the
SCBC assay. The donor-to-donor variability in poly-
functionality could be caused by a population-level
shift of cytokine profiles, or the alteration of specific
polyfunctional subpopulations. To better understand
this variation, we first sought to use a conventional
heatmap to visualize cytokine production from all sin-
gle cells across four donors. The heat map data
visualization in Fig. 2c gives a high-level indication
that the analyzed single CAR-T cells exhibit signifi-
cant differences in the combinations and intensities
Fig. 1 Multiplexing single cell measurement of CAR-T cells in microchambers. a Schematic outline of CD19TL19 CAR-T cell generation, sorting and
stimulation. The CD19-BB-z transgene lentiviral vector was used for CAR-T cell generation. CAR-T cells were sorted and then stimulated by anti-CAR
beads prior to the SCBC assay. b The validated 16-plex panel including 4 groups of cytokines: effector, stimulatory, regulator and inflammatory. c Major
work flow for single-cell functional proteomic analysis. (i) Schematic depiction of a microchamber fabricated in PDMS used for isolating single cells and
assaying a panel of proteins/cytokines secreted from the entrapped cell with an antibody barcode array patterned on the glass slide. Each device has
12,000 microchambers. (ii) Motorized miscopy allows for automated imaging of the entire microchamber PDMS device for locating and counting T
cells in microchambers. Protein secretion profile is obtained by quantifying the fluorescence signals corresponding to single-cell secretions in each
microchamber. Overlay of these two data sets allows for the identification of single-cell protein secretion profiles. (iii) Quantitative analysis, statistics and
advanced informatics (e.g., CytoSpeak package) were applied in this project to investigate the effector function (cytokine) landscape of single CAR-T cells. d
A representative measurement of IFN-γ in supernatants from CAR-T cells stimulated by either IgG beads or anti-CAR beads by ELISA
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Fig. 2 CAR-T cells show high polyfunctionality in anti-tumor effector and stimulatory functions. a Polyfunctional breakdown of CD3+, CD4+ and
CD8+ T cells at the single-cell level across 4 donors. The T cells of donors 1, 3 and 4 show a 6 to 47-fold increase in overall polyfunctionality when
stimulated with anti-CAR beads, compared to IgG stimulation. By comparison, donor 2 only shows a 2-fold increase. b Polyfunctional strength
index (PSI) computed for CD3+, CD4+, and CD8+ T cells at the single-cell level across 4 donors. The profiles of donors 1, 3 and 4 is dominated by
effector and stimulatory cytokine subsets. c Heat map and dendrogram visualization applied to the CD3 T cell secretion data. There is one heat
map per donor, and each column corresponds to a single cytokine, while rows correspond to individual cells. Non-secreting cells are excluded
from the heat maps. The colors indicate log transformed secretion intensities (red = low, green = high). At a high level, this visualization illustrates
some differences across donors and which cytokines are commonly secreted in tandem. However, the clustering is done individually per donor,
and it is difficult to map clusters to functional subsets
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(red = low, green = high) of secreted proteins. How-
ever, it remains difficult to clearly visualize many
functional subsets from heterogeneous CAR-T cells
across donors.
Limitations of conventional PCA and other standard
visualizations in dissecting high-dimensional, single-cell,
proteomic data of CAR-T cells
We further explore other standard bioinformatics tools
in visualizing this high-dimensional data set. In this
standard bar graph visualization of the functional groups
secreted by the four donors’ CD4+ CAR-T cells (Fig. 3a),
the dimensionality of the data makes it cumbersome to
see which are the major functional groups being secreted
by each donor, as well as the largest fold differences
across donors. An alternative approach to visualizing
high-dimensional datasets is to first reduce the dimen-
sionality of the data, while retaining as much of the
original information as possible. PCA (principal compo-
nent analysis) is a common dimensionality reduction
technique which uses an orthogonal transformation to
convert the original dataset of possibly correlated
variables into a set of linearly uncorrelated principal
components, where the number of components is
smaller than the number of original variables. The trans-
formation is defined in such a way that the first principal
component has the largest possible variance (accounting
for as much variability as possible within the dataset),
followed by the second component, and so on. While
reducing the dimensionality to two principal compo-
nents may still result in some loss of information, the
benefit is that the transformed data points can then be
visualized on a two-dimensional scatterplot. Addition-
ally, key differences within the transformed data should
be magnified through this transformation. Figs. 3b-c dis-
plays the results of applying PCA to the 4-donor CD4+
CAR-T secretion dataset. Each cell’s secretions (signal
intensity of each cytokine) are log transformed prior
to dimensionality reduction. Fig. 3b shows a scatter-
plot of the transformed data color-coded by donor,
while Fig. 3c shows the same data color-coded by
some of the individual cytokines. The combination of
these graphs does reveal additional information about
donor response differences and expressed polyfunc-
tional subsets, such as the lower overall polyfunction-
ality of donor 2, or the higher Granzyme B + MIP-
1α + polyfunctionality of donor 1. A similar pattern
of cytokine secretions was seen in the CD8+ CAR-T
cells of all 4 donors (Additional file 7). However, two
key issues still exist with this visualization: (1) it is
difficult to infer which high-dimensional cytokine sub-
sets are driving the polyfunctionality of each sample,
and (2) it is unclear what are the more granular poly-
functional differences across the analyzed donor
samples. Other methods such as viSNE (Additional
file 8) that map high-dimensional cytometry data onto
two dimensions, yet conserve the high-dimensional
structure of the data, improve the ability to distin-
guish cell subpopulations [28, 29]. However, the poly-
functional breakdown of the samples remains unclear
when this visualization is used. In the context of
polyfunctional T cell analysis, the routine practice has
been to manually enumerate the major polyfunctional
subsets by quantifying the cell count in each of the
possible cytokine combinations, which serves well the
ability to distinguish polyfunctional T cell subsets but
loses the relationship between subsets or the hier-
archical structure of the population. We hereby
propose two alternative visualizations, polyfunctional
heat map and polyfunctional activated topology prin-
cipal component analysis (PAT PCA) which in tan-
dem work to solve these problems.
Polyfunctional heat map to highlight distinct
polyfunctional T cell subsets and the heterogeneity
within a cell population
To distinguish all polyfunctional subsets within a sample and
dissect the population architecture, we developed a new
polyfunctional heat map visualization. This visualization,
shown in Fig. 4a for CD4+ CAR-T cells and Fig. 5a for CD8
+ CAR-T cells, displays the major functional subsets secreted
across the 4 donor samples. The heat maps are color-coded
from light to dark, depending on the frequency of the poly-
functional cell subsets. The four rows of squares correspond
to the four donors; each column corresponds to a polyfunc-
tional group of cytokines that was expressed in at least one
of the four samples. To condense the large number of func-
tional groups arising from the high dimensionality of the
data set, we use agglomerative hierarchical (complete link-
age) clustering to attain a condensed set of functional groups
that still faithfully represent the overall secretion profile of
the donors. Using a Euclidean distance to measure similarity
between functional groups, each unique group is input into
the clustering algorithm as a 16-dimensional vector of 1 s
and 0 s, corresponding to the presence or absence, respect-
ively, of each cytokine in the group. We define the minimum
permitted similarity value to perform a clustering operation,
to ensure that clusters do not contain functional groups that
are too distinct from each other. The resulting clusters and
their frequencies are displayed in the functional heat map,
with the size of the cytokine dots below each column repre-
senting the frequency of the corresponding cytokine in the
cluster. As seen in Fig. 4a, donor 1, closely followed by donor
4, has the highest frequencies of most expressed functional
groups. Donor 3 is less polyfunctional, while donor 2 has the
least polyfunctional groups. The group GM-CSF, Granzyme
B, IL-13 and TNF-α is expressed exclusively by the CD4+
Xue et al. Journal for ImmunoTherapy of Cancer  (2017) 5:85 Page 8 of 16
Fig. 3 Higher dimensional data is difficult to visualize concisely. a With highly-multiplexed single-cell data, displaying the breakdown of
different functional groups being secreted by a sample can increase by up to a factor of 2× with the addition of x cytokines. When this
analysis is performed across a set of donors or stimulation conditions, effectively highlighting the key secretion differences is challenging.
In this standard bar graph visualization of functional groups secreted by CD4+ CAR-T cells of four donors, it is cumbersome to see which
are the major functional groups being secreted by each donor, and what are the biggest fold differences across donors. b-c Reducing the
dimensionality of the dataset is a different approach to more effective and understandable visualizations. PCA (principal component analysis) uses an
orthogonal transformation to convert the original dataset into a set of linearly uncorrelated principal components, where the number of components
is smaller than the number of original variables. The transformation is defined in such a way that the first principal component has the largest possible
variance (accounting for as much variability as possible within the dataset), followed by the second component, and so on. While reducing the
dimensionality to two principal components may still result in some loss of information, the benefit is that the transformed data points can then be
visualized on a two-dimensional scatterplot. In this figure, PCA is applied to the 4-donor CD4+ CAR-T secretion dataset. Each cell’s secretions (signal
intensity of each cytokine) are log transformed prior to dimensionality reduction. b is color-coded by donor, while c is color-coded by some of the
individual cytokines. The combination of these graphs reveals some information, such as the low overall polyfunctionality of donor 2, and the high
Granzyme B + MIP-1a + polyfunctionality of Donor 4. However, more detailed information about upregulated and/or distinct polyfunctional subsets is
less clear
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CARs of donors 1 and 4, but not by the CARs of donor 2 or
donor 3. Similarly, the 7-plex group containing GM-CSF,
Granzyme B, IFN-γ, IL-8, IL-13, MIP-1α, and TNF-α is
unique to these two donors, revealing functional differences
of these CAR cells relative to those of donors 2 and 3 at a
high degree of granularity. Functional groups not containing
Fig. 4 Polyfunctional heat map and PAT PCA reveal distinct CD4+ CAR-T cell profiles across donors. a Polyfunctional heat map displaying
major functional subsets secreted across the 4 donors’ CD4+ CAR-T samples. Hierarchical clustering is applied to attain a condensed set
of functional groups that still faithfully represent the overall profile of the donors. The color-coding indicates how commonly each donor
secrets the corresponding functional group/cluster. Donor 1, closely followed by donor 4, has the highest frequencies of most expressed
functional groups. Donor 3 is less polyfunctional, while donor 2 has virtually no secreted polyfunctional groups. The group GM-CSF,
Granzyme B, IL-13 and TNF-α is expressed exclusively by the CD4+ CARs of donors 1 and 4, but not by the CARs of donor 2 or donor 3.
Similarly, the 7-plex group containing GM-CSF, Granzyme B, IFN-γ, IL-8, IL-13, MIP-1α, and TNF-α is unique to these two donors. Functional
groups not containing GM-CSF or IL-13 are expressed at similar frequencies by donor 3 as they are by donors 1 and 4. b PAT PCA visualization of the
same dataset. Data points are color-coded based on donor. Those representing the same functional group are randomly offset, but remain within a
radius proportional to the secretion frequency of the corresponding group (i.e., large groups = large circles, small groups = small circles). The principal
components are labeled according to their correlation with specific cytokines. The lack of donor 2 (orange) subsets indicates the lower polyfunctionality
of this sample, while the presence of numerous donor 1 (blue) and 4 (green) groups in the right area of the graph indicates the highly-polyfunctional
makeup of these two samples. Donor 3 has generally less polyfunctional subsets, typically including combinations of Granzyme B, MIP-1α, IL-8, and
TNF-α but lacking IFN-γ, IL-13, and GM-CSF. Donor 4 largely spans the polyfunctional profiles of both donors 1 and 3
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GM-CSF or IL-13 are expressed at similar frequencies by
donor 3 as they are by donors 1 and 4. As seen in Fig. 5a,
the CD8+ CAR cells similarly show donors 1 and 4 to be
significantly more polyfunctional than donors 2 and 3, and
also uniquely secrete the 7-plex group containing GM-CSF,
Granzyme B, IFN-γ, IL-8, IL-13, MIP-1α, and TNF-α. Donor
Fig. 5 Polyfunctional heat map and PAT PCA reveal distinct CD8+ CAR-T cell profiles across donors. a Polyfunctional heat map displaying major functional
subsets secreted across the 4 donors’ CD8+ CAR-T samples. Hierarchical clustering is applied to attain a condensed set of functional groups that still
faithfully represent the overall profile of the donors. The color-coding indicates how commonly each donor secrets the corresponding functional group/
cluster. Donors 1 and 4 are significantly more polyfunctional than donors 2 and 3, and also uniquely secrete the 7-plex group containing GM-CSF,
Granzyme B, IFN-γ, IL-8, IL-13, MIP-1α, and TNF-α. Donor 1 has a higher number of unique polyfunctional groups than donor 4, particularly groups not
containing IL-8. The only polyfunctional groups secreted by all four donors contain Granzyme B, MIP-1 α with smaller amounts of IFN- γ. b PAT PCA
visualization of the same dataset. Data points are color-coded based on donor. Those representing the same functional group are randomly offset, but
remain within a radius proportional to the secretion frequency of the corresponding group (i.e., large groups = large circles, small groups = small
circles). The principal components are labeled according to their correlation with specific cytokines. Like the CD4+ CAR-T samples, donor 2 (orange)
has low polyfunctionality, donors 1 (blue) and 4 (green) are highly polyfunctional. Donor 3 has generally less polyfunctional subsets often comprised of
combinations of Granzyme B, MIP-1α, IL-8, and TNF-α but lacks IFN-γ, and IL-13. Donor 4 largely spans the polyfunctional profiles of both donors 1 and
3, which can also be seen in the heat map
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1 has a higher number of unique polyfunctional groups than
donor 4, particularly groups not containing IL-8. The only
polyfunctional groups secreted by all four donors contain
Granzyme B, MIP-1 α with smaller amounts of IFN- γ.
PAT PCA to further visualize distinct polyfunctional T cell
subsets and a complex landscape of CD19-specific immune
response
In addition to the heat map visualization, we propose a
modified PCA visualization named PAT PCA illustrated
in Additional file 2. We use this visualization to help
reveal a complex landscape of polyfunctional subsets of
CAR-T cells in response to antigen-specific stimulation
across donors. Figs. 4b and 5b show PAT PCA visualiza-
tions of the same single-cell-resolution CD4+/CD8+
CAR results as the heat maps in Figs. 4a and 5a, respect-
ively. Similarly for the hierarchical clustering input, we
apply PCA on a binarized dataset (0 = no secretion,
1 = secretion), to focus on visualizing combinatorial
differences, rather than intensity differences. In the
resulting scatterplot visualization, each color-coded dot
represented a single-cell from one of the four donors,
respectively, in which the larger color-coded circles rep-
resented a unique polyfunctional subset. The colors of
the subsets identified the sample where this subset was
most frequent (i.e., largest as a percentage of the
sample). The functional groups (columns) in the heat
map are represented by a circle in the corresponding
PAT PCA graph. The size of the circles corresponds to
the frequency of the group; the number of cells (dots)
within each group indicates how frequently the sample
of the corresponding color secreted the group. The
makeup of the two principal components PC1 and PC2
is indicated by the listed cytokines, with the composition
of PC1 indicating the main drivers of polyfunctionality.
In both graphs, PC1 is a combination of the seven
dominant secretors of the anti-CAR stimulated cells:
effector cytokines Granzyme B, MIP-1α, IFN-γ, and
TNF-α; stimulatory cytokines GM-CSF and IL-8; and
the regulatory cytokine IL-13. As a result, the highly-
polyfunctional groups are farther along (on the right-
side of ) this axis. PC2 differed between CD4 and
CD8 cells. In the CD4 case, groups towards the top
tend to have more Granzyme B, IL-8 and TNF-α,
while groups near the bottom more often contain IL-
13, IFN-γ and MIP-1α. In the CD8 case, groups near
the top more commonly secreted IFN-γ, IL-13 and
GM-CSF, while groups near the bottom more com-
monly secreted Granzyme B, IL-8 and MIP-1α.
Plotting the polyfunctional subsets in such a manner
allows overall similarities and differences in the donor
profiles to emerge. The lack of donor 2 (orange)
subsets indicated the lower polyfunctionality of this
sample, while the presence of numerous donor 1
(blue) and donor 4 (green) groups in the right area of
the graph indicated the highly-polyfunctional makeup
of these two samples. Donor 3 has fewer polyfunc-
tional subsets mostly comprised of combinations of
Granzyme B, MIP-1α, IL-8, and TNF-α but lacking
IFN-γ, IL-13, and in the case of CD4+ cells, GM-CSF.
Donor 4 largely spans the polyfunctional profiles of
both donors 1 and 3, which can also be seen in the
heat maps. Capturing the full polyfunctional landscape
of each sample is critical to effectively analyzing this
data, as well as identifying the major subsets contrib-
uting to differences between samples/donors. The
presented polyfunctional heat map and PAT PCA
graphs are effective at achieving these objectives, both
individually and together, and provide the first land-
scape of effector function phenotypes of CD19 CAR-
T cells in response to antigen-specific challenge.
Discussion
Defining clinical relevant functional attributes of CAR-T
products has been a primary objective of pre-infusion
analytics strategy of CAR-T cell therapy, yet key attri-
butes that are associated with efficacy or safety are still
unknown [30]. This is mainly due to two reasons. Firstly,
CAR-T final product is a complex live cell population
with thousands of unique phenotypes and myriad func-
tions that peripheral blood derived T cells possess [31].
Individual CAR-T cell may respond in a markedly differ-
ent manner to antigen specific stimulation as defined by
a host of immune effector cytokines secreted. Secondly,
the most commonly utilized assays to assess CAR-T
functions in the context of CD19 CAR-T therapies are
cytotoxicity assay and interferon gamma release assay
[30]. In both cases, CAR-T cells are co-cultured at a
population level with target cells, a cell line that
expresses CAR specific tumor antigen. Measuring one
averaged signal, both assays fail to take into account the
full diversity of T cell functions and are not adequate to
provide complete data for clinical correlations [30]. As
such, a highly multiplexed, single cell approach is
needed for comprehensive pre-infusion assessment of
CAR-T product protein secretion to enable biomarker
development. We propose the SCBC platform, which
measures a broad range of up to 45 secreted proteins at
the single cell level, in combination with the newly de-
veloped polyfunctionality analysis software, is well suited
to address this pressing need. In this study, we measured
16 immune functions including anti-tumor effector,
stimulatory, inflammatory, and regulatory cytokines at
the single-cell level on human CD19 CAR-T cells (Fig. 1).
An elevated cytokine production with dominant anti-
tumor effector profile from CD19 CAR-T cells in response
to antigen-specific stimulation was observed across all 4
donors (Fig. 2 and Additional file 3). Polyfunctional subsets
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were further analyzed and visualized using newly developed
bioinformatics tools, polyfunctional heat map and PAT
PCA (Figs. 4 and 5). All together, we demonstrated that the
SCBC platform represents a new platform that enables a
comprehensive profiling of CAR-T cell cytokine/chemokine
production and supports correlative analysis for biomarker
discovery in pre-infusion CAR-T products.
Initial evidence suggests that polyfunctional CAR-T cells
may serve as a useful biomarker for efficacy. Dynamic
polyfunctionality analysis of adoptively transferred MART-
1-specific TCR-engineered T cells showed that TNF-
α+IFN-γ+ polyfunctional T cell delayed tumor relapse [27].
Furthermore, a study comparing in vitro functions of
CD19 CAR-T cells generated from different CAR struc-
tures showed that polyfunctionality rather than cytotoxicity
of the CAR-T cells was a better predictor of therapy effi-
cacy in vivo [32]. The observation that persisting CAR-T
cells in CLL complete responders remain polyfunctional
4 years after infusion suggests an association between poly-
functional CAR-T cells with persisting response [9]. The
significance of T cell polyfunctionality in product
characterization as well as clinical biomarkers led us to
bring this metric to the forefront of our data analysis and
visualizations. We first quantitated the level of polyfunc-
tionality using PSI analysis which results in a polyfunction-
ality score for each donor (Fig. 2a and b). Overall, an
increase in polyfunctionality of CAR-T cells in response to
anti-CAR bead stimulation was observed in all four
donors, with significant donor-to-donor heterogeneity (Fig.
2). CAR-T cells from donors 1 and 4 have the highest poly-
functionality, whereas CAR-T cells from donor 2 have the
least. The polyfunctionality was predominated by effector
cytokine profiles, which is consistent with the high potency
observed with CD19 CAR in previous clinical trials.
We then sought to breakdown the unique combinations
of cytokine subsets secreted by a sample. The further
analysis requires bioinformatics tools as the number of pos-
sible subsets can increase by up to a factor of 2n with the
addition of n cytokines. On top of this, when analyzing
differences across a set of donors or stimulation conditions,
effectively highlighting the key polyfunctional differences is
challenging. Previously developed single cell analysis bio-
informatics tools, however, do not fit the purpose of poly-
functional analysis, especially for the comparison between
multiple donors [29, 33]. For example, conventional heatmap
can indicate heterogeneity among single cells within one
donor at a high level, but it cannot map functional subsets of
different samples in the same space, therefore making multi-
donor comparison very difficult (Fig. 2c). While conventional
PCA and viSNE can map multiple donors in the same space,
neither can identify polyfunctional subsets that drive the dif-
ferentiations between donors at a high level of granularity
(Fig. 3 and Additional file 8). To address this need, we devel-
oped two informatics visualization tools, namely a
polyfunctional heat map and a PAT PCA scatterplot
visualization, which are able to capture the full landscape of
complex polyfunctional subsets within each donor, and iden-
tify major subsets that are different between donors and the
driving factors for these differences. For example, polyfunc-
tional heatmap showed while all four donors have polyfunc-
tional subsets secreting Granzyme B, MIP-1α and IFN-γ,
only donor 1 and donor 4 have a highly polyfunctional sub-
sets secreting GM-CSF, Granzyme B, IFN-γ, IL-8, IL-13,
MIP-1α and TNF-α. PAT PCA visualization further reveals
that the polyfunctional subsets of donor 3 are driven mainly
by IL-8, Granzyme B, TNF-α (CD4) and MIP-1α (CD8)
whereas those of donor 1 typically include IFN-γ and IL-13.
Overall, we saw a convincing increase in the clarity of poly-
functional heatmaps and PAT PCA over other state of the
art visualizations, demonstrating the overarching importance
of developing visualizations that highlight polyfunctionality
in sample characterization and differentiation. As with all
novel, high dimensional data, one key challenge is how to ef-
fectively use the data. Future studies will explore other
extensions and optimizations to the presented polyfunction-
ality visualizations with larger datasets.
The presented single cell analysis platform is spun out
from previous academic prototype with rigid validations
and significant upgrades [18]. The current data acquisition
and analysis platform features: (1) measurements of true
protein secretion from single cells residing in a nanowell,
representing a more physiological environment than any
other available single cell technology. (2) an automated ac-
quisition process with data integrity and minimal user
interference, and (3) an integrated bioinformatics suite for
understanding and highlighting key differences in donor
response (Fig. 1). The readout of the assay is fluoresce in-
tensity of accumulated cytokines over the 16 h incubation
time. Protein concentrations may be inferred using recom-
binant protein standard curves that generated on a separ-
ate or same chip [34]. Temporal protein secretions of
single cells for time-point study can be measured by ana-
lyzing a serial of chips. So far, the platform has been ap-
plied on a broad range of studies, including cytokine
paracrine signaling analysis, malignant cell characterization
and vaccine evaluation in infectious disease [34–36]. Here,
we extended the application to CAR-T analysis, demon-
strating its capability to comprehensively characterize
CAR-T cell pre-infusion products. Future studies on
patient sample analysis, in combination with correlative
studies with clinical responses will likely provide meaning-
ful data for biomarker identification.
How a patient responds to CAR-T therapy is affected by
multiple factors, the function of CAR-T cells, the phenotype
of tumor cells, the engagement of other immune cells, etc.
Although the current study provides in-depth functional
analysis of CAR-T cells, other contributing factors may con-
found the correlation between CAR-T functions with
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clinical responses. To alleviate the confounding effect of
tumor cell variations across patients, a future experiment is
to include single CAR-T cells with autologous tumor cells
in the same microchamber to evaluate patient-specific
CAR-T response. In fact, the presented SCBC system has
been previously applied to the study of cell-cell interactions
by including multiple cells in one microchamber [37, 38].
The fact that only a small number of cells (~ 1 × 104
cells) are required for setting up one SCBC chip
makes the presented technology especially suitable for
CAR-T autologous tumor response studies. In
addition, nanowell-based single cell technologies have
been previously used to study cytotoxicity of single
NK cell or CAR-T cell in response to target cells [39,
40]. By incorporating cell viability staining and mi-
croscopy imaging, a single cell autologous cytotoxicity
assay can be built into the SCBC system, enabling
simultaneously measurement of cytotoxicity and cyto-
kine/chemokine production from one single cell.
Conclusions
We have demonstrated how single-cell multiplexed
proteomics is able to comprehensively characterize
CD19 CAR-T cell product cytokine/chemokine profiles.
Our single-cell analysis has, for the first time, revealed
the multifunctional heterogeneity of CD19 CAR-T cell
products by antigen-specific stimulation. Through the
SCBC, we measured CAR-T cell secretion profiles across
a panel of 16 key immune functions, and noted clear
distinctions in the range of single-cell responses across
each of four donors. We additionally developed new
polyfunctional heat map and PAT PCA visualizations to
deconvolute single-cell-level differences across donor
responses, and to provide an in-depth understanding of
the polyfunctional subsets driving each donor’s re-
sponses. Although the result presented here are based
on CAR-T cells from healthy donor materials, it illus-
trates the necessity and provide a possible blueprint for
guiding CAR-T product pre-infusion assessment. The
ability to precisely dissect single-cell, polyfunctional
heterogeneity supports a road map for correlative
discoveries on the role of polyfunctional CAR-T cells in
clinical responses and has the potential to greatly impact
CAR-T therapy optimization.
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Additional file 1: Table S1. 16-Plex SCBC Antibody Panel. (PDF 2103 kb)
Additional file 2: Figure S3. Overview of data transformations for PAT PCA.
A: An illustrative example showing how raw single-cell data (signal intensities)
from a single-cell multiplex cytokine assay are transformed. The polyfunctional
group of each cell is found along with unique groups (encoded by a vector of
0 s and 1 s) and their frequencies. An adjusted frequency n, weighted by poly-
functionality, is computed per group. Each vector is included n times and this
resulting dataset is transformed using PCA. (PDF 2103 kb)
Additional file 3: Figure S1. CAR-specific stimulation induces multiple
cytokine production at the single-cell level. Cytokine secretions of total
CD3 T cells, CD4 T cells and CD8 T cells, all stimulated by anti-CAR beads,
are shown across 4 donors and compared to the control secretion profile.
The analyzed 16-plex panel includes 4 color-coded groups of cytokines:
effector (green), stimulatory (blue), regulatory (yellow) and inflammatory
(red). Low secretion percentages, as well as secretions with an average
signal noise ratio (SNR) < 2 are labeled not significant (gray). (PDF 2103 kb)
Additional file 4: Figure S6. Validation of the antibodies in the 16-plex
single-cell panel. (A) standard RFU/protein curve for the 16-plex panel. Antibody
pairs from multiple manufacturers were tested for sensitivity with recombinant
protein by titrating recombinant protein cocktails (5, 15.8, 50, 158, 500, 1580 and
5000 pg/mL) to produce a standard RFU/protein curve. (B) Antibody pairs were
tested for specificity by spiking 1000 pg/mL protein standards for each antibody
on the panel. Antibody pairs were then evaluated for cross reactivity within the
panel. Antibodies were considered specific when the antibody pair had an SNR
>10. (PDF 2103 kb)
Additional file 5: Figure S7. Validation of the 16-plex cytokine panel on
the SCBC platform. (A) A representative signal distribution of Granzyme B, IFN-
γ and TNF-α from single CD8 T cells at the SCBC platform. (B) A representative
ICS data of IFN-γ and TNF-α secreting CD8 T cells. (C) A pooled comparison
data of IFN-γ and TNF-α secreting CD8 T cells between SCBC and ICS. (D) The
correlation of 16 protein secretion levels between single-cell averages from
two independent experiments (x, y axes: % of cytokine-secreting single CD8 T
cells). (E) A representative scatter plots of Granzyme B and IL-8 from individual
experiments. (PDF 3044 kb)
Additional file 6: Figure S2. The level of cytokine secretion from single
cells and populations upon anti-CAR bead stimulation of CD19 CAR-T cells.
At both the single-cell level and bulk-level, an overall increase in the intensity
of effector and stimulatory cytokine secretions was observed with anti-CAR
bead stimulation (orange) compared to control IgG bead stimulation (blue).
While bulk-level measurements only show an average intensity per cytokine
of the entire cell sample, single-cell level measurements present a full distribution
of cell-by-cell secretion intensities. Levels of upregulation are consistent between
the bulk-level measurement and single-cell level measurement across donors,
with donor 2 having very small increases compared to the other three donors at
both levels. (PDF 2103 kb)
Additional file 7: Figure S4. Higher dimensional data is difficult to
visualize concisely. (A) In this standard bar graph visualization of functional
groups secreted by CD4+ CAR-T cells of four donors, it is cumbersome to
see which are the major functional groups being secreted by each donor,
and what are the biggest fold differences across donors. (B-C) Reducing the
dimensionality of the dataset is a different approach to more effective and
understandable visualizations. In this figure, PCA is applied to the 4-donor
CAR-T secretion dataset. Each cell’s secretions (signal intensity of each cytokine)
are log transformed prior to dimensionality reduction. (B) is color-coded by
donor, while (C) is color-coded by some of the individual cytokines. The
combination of these graphs reveals some information, such as the low overall
polyfunctionality of donor 2, and the high Granzyme B+MIP-1a+
polyfunctionality of Donor 4. However, more detailed information about
upregulated and/or distinct polyfunctional subsets is less clear. (PDF 2103 kb)
Additional file 8: Figure S5. viSNE visualization of CD4+ CAR-T data.
viSNE is a visualization tool designed to map high-dimensional flow
cytometry data onto two dimensions, while preserving the overall
structure of the data. Similar to PCA, color can be used as a third dimension
in the resulting visualization. In this figure, color is used to indicate (A) the
donor sample of each single CD4+ CAR-T cell or (B) the intensity of individual
cytokine secretions of each CD4+ CAR-T cell. Unlike PCA, which is a linear trans-
formation, the benefit of visNE is its ability to preserve non-linear relationships
across the data. One can infer that a subset of cells in each donor secrete only
Granzyme B, that primarily donors 3 and 4 have cells secreting only TNF-a, and
that donors 1 and 4 both have unique subsets of highly polyfunctional, Granzyme
B + MIP-1a + IFN-g + secreting cells. However, additional donor differences and
specific information about functional groups is fairly limited. A viSNE transform-
ation of the CD8+ CAR-T data gives a similar graph. (PDF 2866 kb)
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